Pulnovo Medical

High-Level Overview

Pulnovo Medical is a China-based medical device company founded in 2013, specializing in innovative treatments for pulmonary hypertension (PH) and heart failure (HF).[1][2][3] It develops the pulmonary artery denervation (PADN) system—a first-in-class device using radiofrequency (RF) ablation to target sympathetic nerves in the pulmonary arteries, reducing pulmonary artery pressure and slowing disease progression.[1][4] Serving patients with unmet needs in cardiovascular care, Pulnovo addresses a critical gap where few effective therapies exist, particularly for PH groups I and II.[1][4] The company has achieved strong growth momentum, including China NMPA approval in 2023, US FDA Breakthrough Device designation in 2021, CE-MDR certification in Europe in March 2025, and a $100 million Series C financing in March 2025 to fuel global trials and commercialization.[1][2][4]

Origin Story

Pulnovo Medical was established in September 2013 in Wuxi, China, as a pioneer in PADN technology, emerging from frontline physician needs for better PH and HF treatments.[1][2][3] Key leaders include Chairwoman and Executive Chair Cynthia Chen, who emphasizes evidence-based innovation, and CEO Jessie Lian Jia.[1][5] Early milestones included the PADN-5 clinical trial launch in August 2014 and acceptance into China's National Innovative Medical Device Special Review Program in December 2017.[2] Pivotal traction came with positive PADN-CFDA trial results announced at TCT 2022, Series B financing in October 2022, and PADN's inclusion in the ESC/ERS guidelines in August 2022, validating its clinical impact.[2][3] These steps propelled Pulnovo from domestic R&D to global ambitions.[1]

Core Differentiators

• Breakthrough PADN Technology: Core RF ablation catheter and generator uniquely denervate pulmonary arteries, backed by 8 patents in cardiac anatomy, physiology, and defects; first to gain PADN inclusion in international guidelines.[1][2][3]
• Regulatory Momentum: US FDA Breakthrough (2021) and Humanitarian Use (2023) designations, China NMPA breakthrough approval (2023), 9F sheath FDA clearance (2024), CE-MDR (2025), and two FDA IDE approvals (Sep 2025) with CMS coverage for PH trials.[1][2][5]
• Global Clinical Pipeline: Multicenter trials underway, including Portugal enrollment (Jun 2024) for PH with left heart disease and upcoming FDA trials for group I/II PH.[3][4][5]
• Leadership and Backing: Led by Cynthia Chen; funded by Qiming Venture Partners, EQT, Lilly Asia Ventures, OrbiMed; recent hires like Global CMO Dr. Francis Duhay (Aug 2025).[1][4][5]

Role in the Broader Tech Landscape

Pulnovo rides the wave of neuromodulation in cardiovascular medtech, targeting the growing PH/HF market—projected to expand due to aging populations and rising heart disease prevalence.[1][4] Timing aligns with regulatory tailwinds: post-COVID emphasis on innovative devices, plus PADN's guideline endorsement, positioning it ahead of competitors lacking similar validations.[2][3] Favorable forces include China's medtech export push, US/EU fast-tracks for breakthroughs, and investor interest in scalable therapies amid limited PH options.[1][4][5] Pulnovo influences the ecosystem by pioneering PADN as a standard, enabling global access via trials and approvals, and fostering physician-led innovation.[3]

Quick Take & Future Outlook

Pulnovo is poised for global commercialization, with 2025-2026 focused on FDA pivotal trials, indication expansions, and market entries in US/EU post-IDE wins.[1][5] Trends like AI-enhanced devices and value-based care will amplify PADN's evidence-based edge, while partnerships with investors like EQT accelerate scaling.[4] Its influence may evolve from China innovator to worldwide PH leader, delivering scalable solutions to millions—echoing its founding mission to transform unmet needs into global standards.[1]